Research
Hormonal
Combination therapy with half-dose rosiglitazone and metformin significantly reduces the incidence of type 2 diabetes in patients with impaired glucose tolerance compared to placebo.
If you have impaired glucose tolerance, combining half-dose rosiglitazone (2mg) and metformin (500mg) twice daily significantly reduces your risk of developing type 2 diabetes (66% relative risk reduction) compared to placebo. This regimen is effective and appears safe with few side effects.
StrongSupportsVERY_HIGH confidence
Significantly fewer patients in the treatment group (n = 14 [14%]) than in the placebo group (n = 41 [39%]) developed incident diabetes (P < 0.0001). The relative risk reduction was 66%, with a 95% confidence interval (CI) of 41 to 80.
Why this rating
Double-blind, randomized, controlled trial with long duration (median 3.9 years) and clear primary endpoint.
Source
Weight and Metabolic Outcomes After 2 Years on a Low-Carbohydrate Versus Low-Fat Diet
Gary D. Foster et al. · Obstetrical & Gynecological Survey · 2010
DOI 10.1097/ogx.0b013e31821342ba
rct · n=307Cited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Long-term weight loss (2 years) is equivalent between low-carbohydrate and low-fat diets when both are combined with comprehensive behavioral interventions.Good
- A low-carbohydrate diet provides superior long-term improvements in HDL cholesterol compared to a low-fat diet, even when weight loss is equivalent.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →